Author:
Stark I.,Mensing C.H.,Sander C.A.
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Appetecchia M, Ferretti E, Carducci M et al. (2006) Malignant glucagonoma. New options of treatment. J Exp Clin Cancer Res 25: 135–139
2. Echenique-Elizondo M, Tuneu Valls A et al. (2004) Glucagonoma and pseudoglucagonoma syndrome. J Pancreas 5: 179–185
3. Faiss S, Pape UF, Bohming M et al. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors- the International Lancreotide and Interferon Alfa Study group. J Clin Oncol 21: 2689–2696
4. Fjallskog ML, Gundin A, Westein JE et al. (2002) Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatinanalogs. Med Oncol 19: 35–42
5. Marinkovich MP, Botella R, Datloff J, Sangueza OP (1995) NME without glucagonoma in patients with liver disease. J Am Acad Dermatol 32: 604–609
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献